title: Decorporation of thorium-228 from the rat by 3,4,3-LIHOPO and DTPA after simulated wound contamination.
abstract: 1. With DTPA as a comparison, the siderophore analogue 3,4,3-LIHOPO has been examined for its ability to remove 228Th nitrate from the rat after subcutaneous (sc) and intramuscular (im) injection to simulate wound contamination. The commencement of treatment was delayed 30 min, 6 h or 1 d and the animals killed at 7 d. 2. In all cases 3,4,3-LIHOPO was appreciably more effective than DTPA although the efficacy of treatment and the relative effectiveness of the ligands decreased rapidly with their delay in administration. 3. Optimum removal with both ligands occurred when initial local administration at 30 min after exposure was followed by repeated intraperitoneal injection at 6 h, 1, 2 and 3 d. Under these conditions the body content of 228Th was reduced to 20% of controls after sc injection and 15% after im injection. The corresponding values using repeated DTPA administration were 80% and 54%. 4. It is concluded that 3,4,3-LIHOPO represents, potentially, a considerable advance on DTPA, the current agent of choice for the treatment of wounds contaminated by 228Th.
authors.affiliation: National Radiological Protection Board, Didcot, Oxon, UK.
authors.forename: G N
authors.initials: GN
authors.lastname: Stradling
authors.forename: S A
authors.initials: SA
authors.lastname: Gray
authors.forename: M J
authors.initials: MJ
authors.lastname: Pearce
authors.forename: I
authors.initials: I
authors.lastname: Wilson
authors.forename: J C
authors.initials: JC
authors.lastname: Moody
authors.forename: R
authors.initials: R
authors.lastname: Burgada
authors.forename: P W
authors.initials: PW
authors.lastname: Durbin
authors.forename: K N
authors.initials: KN
authors.lastname: Raymond
mesh_terms: D000818:Animals; D001372:Aza Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007700:Kinetics; D008024:Ligands; D004369:Pentetic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017970:Thorium Compounds / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D014945:Wound Healing / Q000187:drug effects
chemical_list: D001372:Aza Compounds; D008024:Ligands; D011728:Pyridones; D017970:Thorium Compounds; C076998:N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane; D004369:Pentetic Acid; C036680:thorium nitrate